Skip to search formSkip to main contentSkip to account menu

B3(Fv)-PE38KDEL recombinant immunotoxin

Known as: LMB-2 immunotoxin, Humanized AntiTac Toxin, LMB-2 
A fusion protein consisting of the Fv portion of a monoclonal antibody attached to a 38-kDa fragment of the Pseudomonas exotoxin A (with amino acids… 
National Institutes of Health

Related topics

Related topics

12 relations
ApoptosisB-LymphocytesIL2RA protein, humanPeptide Elongation Factor 2

Broader (3)

ExotoxinsImmunotoxinsMonoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Immunoconjugates in the management of hairy cell leukemia.
2012
2012
Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary
Pseudomonas exotoxin-based immunotoxins, including LMB-2 (antiTac(Fv)-PE38), are proposed to traffic to the trans-Golgi network… 
2011
2011
Synergistic Antitumor Activity of Anti-CD25 Recombinant Immunotoxin LMB-2 with Chemotherapy
Purpose: Although anti-CD25 recombinant immunotoxin LMB-2 is effective against CD25+ hairy cell leukemia, activity against more… 
2011
2011
Regression of Adult T-Cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 Preceded by Chemotherapy
Abstract 2575 Background: Adult T-cell leukemia (ATL) is a highly aggressive CD25+ HTLV-1-associated malignancy with median… 
2011
2011
Renal excretion of recombinant immunotoxins containing pseudomonas exotoxin.
Recombinant immunotoxins BL22 (CAT-3888) and LMB-2, composed of Fv fragments of anti-CD22 and CD25 MAbs, respectively, have… 
2011
2011
Cancer Therapy : Preclinical Synergistic Antitumor Activity of Anti-CD 25 Recombinant Immunotoxin LMB-2 with Chemotherapy
Purpose: Although anti-CD25 recombinant immunotoxin LMB-2 is effective against CD25þ hairy cell leukemia, activity against more… 
2010
2010
Abstract 5606: Preclinical and clinical development of anti-CD25 recombinant immunotoxin LMB-2 in combination with chemotherapy for the treatment of adult T-cell leukemia
LMB-2, previously called anti-Tac(Fv)-PE38, is a recombinant immunotoxin containing the variable domains of the anti-CD25 Mab and… 
2007
2007
VivoPartial Reduction in Regulatory T Cells In Metastatic Melanoma Induces a Selective Immunotoxin, LMB-2, to Patients with Administration of a CD25-Directed
CD25 (cid:1) CD4 (cid:1) T regulatory (Treg) cells regulate peripheral self tolerance and possess the ability to suppress… 
Review
2006
Review
2006
Immunotoxins in the treatment of refractory hairy cell leukemia.
1993
1993
Recombinant immunotoxins: new therapeutic agents for cancer treatment.
We have developed new agents for the treatment of cancer by genetically modifying Pseudomonas exotoxin. We have deleted the cell… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)